TORONTO, Sept. 14, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that its lead candidate, MSP-1014…

Source

Previous articlePharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
Next articlePT262 – Carlene MacMillan, M.D. – Set, Setting, and Systems: Adding Insurance to the Conversation